Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.
Domain: Therapeutics & Diagnostics, Other
Therapeutics & Diagnostics, Vaccines
Contact: Avenue de la Roseraie 64
1205 Geneva / GE
P: +41 22 372 38 01

http://www.tolerys.com
Find an actor

LS2 Annual Meeting 201812.02.2018

The biggest Life Sciences conference in Switzerland takes place at the University of Lausanne February 12-13, 2018

Bilan - Les Métiers de Demain

Le magazine référence nous informe des nouvelles formations et de leur impact sur l'avenir des métiers de la santé...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn